OncoMatch/Clinical Trials/NCT04510636
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Is NCT04510636 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Bendamustine Hydrochloride for classical hodgkin lymphoma.
Treatment: Pembrolizumab · Bendamustine Hydrochloride — This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline — first line
Must have received at least standard first line chemotherapy for classical Hodgkin Lymphoma, containing an anthracycline
Cannot have received: bendamustine
Patient has received prior treatment with bendamustine, either as monotherapy or as part of a combination regimen
Cannot have received: allogeneic hematopoietic stem cell transplant
Patient has undergone prior allogeneic hematopoietic stem cell transplant
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Demonstrate adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify